Tyrosine Kinase Inhibitors: all 10,469 studies that test it
Page 9 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06760819Phase 2
- Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic CancerNot yet recruitingNCT06759090Phase 2
- Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CMLRecruitingNCT06757855Phase 1/2
- Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruitingNCT06757647Phase 2
- Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell LymphomaNot yet recruitingNCT06757387Phase 1/2
- Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher SeverityRecruitingNCT06756061Phase 2
- Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALLRecruitingNCT06754267Phase 2
- A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06753747Phase 1/2
- Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung CancerNot yet recruitingNCT06752408Phase 2
- Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract CarcinomaRecruitingNCT06749730Phase 2
- Liposomal Irinotecan and Apatinib in ES-SCLCRecruitingNCT06749691Phase 2
- Avapritinib Rollover StudyRecruitingNCT06748001Phase 4
- Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs TherapyNot yet recruitingNCT06746961Phase 1/2
- A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.Not yet recruitingNCT06746545Phase 2
- A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal CancerNot yet recruitingNCT06745193Phase 2
- Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic ImpairmentRecruitingNCT06740799Phase 1
- TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular CarcinomaRecruitingNCT06740370Not applicable
- Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingNCT06739395Phase 2
- Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's TransformationRecruitingNCT06735664Phase 1
- A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive MutationsRecruitingNCT06735391Phase 3
- Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)RecruitingNCT06733051Phase 2
- Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS LymphomaRecruitingNCT06730542Phase 1
- Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS PatientsRecruitingNCT06730126Phase 2
- A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementRecruitingNCT06728410Phase 2
- A Study of Pirtobrutinib in Participants With Immune ThrombocytopeniaRecruitingNCT06721013Phase 1/2
- Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung CancerRecruitingNCT06719700Phase 2
- Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical TacrolimusRecruitingNCT06719024Phase 2/3
- Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain MetastasisRecruitingNCT06718933Phase 1/2
- Pyrotinib in HER2-positive Early Breast CancerNot yet recruitingNCT06718335Not applicable
- JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasRecruitingNCT06716658Phase 2
- A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06716138Phase 1
- Q702 for the Treatment of Patients With Hematologic MalignanciesRecruitingNCT06712810Phase 1
- Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLCNot yet recruitingNCT06709274Not applicable
- Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract CancerRecruitingNCT06708858Phase 2
- HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid TumoursRecruitingNCT06708663Phase 1/2
- A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 MutationsRecruitingNCT06706076Phase 1/2
- Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II TrialRecruitingNCT06700798Phase 2
- Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCCNot yet recruitingNCT06699498Phase 2
- A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIARecruitingNCT06698822Phase 2
- Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)RecruitingNCT06698250Phase 2
- Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer PatientsNot yet recruitingNCT06697990Phase 2
- Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive TreatmentRecruitingNCT06696183Phase 2
- First-line Treatment of Advanced/unresectable DDLPSNot yet recruitingNCT06694324Phase 2
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
- Tofacitinib in Patients With Amyotrophic Lateral SclerosisNot yet recruitingNCT06689982Early Phase 1
- JAK Inhibitor Dose TAPering Strategy StudyRecruitingNCT06687551Phase 4
- APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced STRecruitingNCT06687070Phase 1
- Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal CancerRecruitingNCT06685276Phase 2
- Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06684600Phase 2
- Upadacitinib as a Novel Treatment for Refractory Eyelid DermatitisRecruitingNCT06684522Early Phase 1
- Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung CancerNot yet recruitingNCT06682884Phase 2
- Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host DiseaseRecruitingNCT06682169Phase 3
- Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)Not yet recruitingNCT06681285Phase 2
- Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast CancerNot yet recruitingNCT06678230Phase 2
- Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT06675123Phase 1
- Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical MutationsRecruitingNCT06674343Phase 3
- Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsRecruitingNCT06673628Phase 2
- A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLCNot yet recruitingNCT06672068Phase 2
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesRecruitingNCT06671483Phase 3
- Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial TreatmentRecruitingNCT06669572Phase 2
- Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial RemissionNot yet recruitingNCT06669143Phase 2
- Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid LeukemiaNot yet recruitingNCT06667973Phase 2
- Study of ACR-2316 in Specific Advanced Solid TumorsRecruitingNCT06667141Phase 1/2
- A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06667076Phase 2
- Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line TreatmentNot yet recruitingNCT06662877Phase 2/3
- Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney CancerRecruitingNCT06661720Phase 3
- Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative ColitisRecruitingNCT06660693Phase 3
- Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic TherapyRecruitingNCT06660355Phase 2
- Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid TumorsRecruitingNCT06658353Phase 3
- Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract CarcinomaNot yet recruitingNCT06656559Phase 2
- A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell LymphomaNot yet recruitingNCT06656221Phase 2
- A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell CarcinomaNot yet recruitingNCT06656091Phase 3
- A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT06655246Phase 1
- A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.Not yet recruitingNCT06654947Phase 2
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritisRecruitingNCT06654882Phase 3
- IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 TrialRecruitingNCT06654011Phase 2
- Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor CellsRecruitingNCT06653777Phase 2
- High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKIRecruitingNCT06652048Phase 2
- Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart FailureRecruitingNCT06651970Phase 4
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingNCT06649812Phase 2
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingNCT06649331Phase 2
- Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingNCT06648096Phase 1/2
- Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）RecruitingNCT06647940Phase 2
- Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell CarcinomaRecruitingNCT06646588Phase 2
- High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)Not yet recruitingNCT06646211Phase 2
- Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)Not yet recruitingNCT06644313Phase 2
- Nintedanib Treatment in Unicentric Castleman DiseaseNot yet recruitingNCT06643091Phase 2
- Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal MetastasisRecruitingNCT06643000Not applicable
- A Study of Olverembatinib in SDH-deficient GIST.RecruitingNCT06640361Phase 3
- A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung CancerRecruitingNCT06631989Phase 1/2
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVIDRecruitingNCT06631287Phase 3
- 5G-RUBY: Avutometinib and Defactinib in Malignant Brain TumoursRecruitingNCT06630260Phase 1/2
- A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)RecruitingNCT06630234Phase 1/2
- A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative StudyRecruitingNCT06630091Phase 2
- Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid LeukemiaRecruitingNCT06629584Phase 2
- Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of SepsisNot yet recruitingNCT06626984Phase 1/2
- TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITISNot yet recruitingNCT06625450Phase 4
- TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTTRecruitingNCT06622031Not applicable
- Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)Not yet recruitingNCT06621095Phase 2
- A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)RecruitingNCT06619561Phase 2